Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2008 Nov 18;99(12):2020–2028. doi: 10.1038/sj.bjc.6604783

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2008 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effects of CI-1040 in a mouse xenograft model. (A) CI-1040-treated cells produced small tumour nodules in the peritoneal cavity. However, the diluent control-treated cells grew much larger i.p. tumours in KRAS mutant MDAH2774 cells. (B) In contrast, there were no differences in tumour weights between CI-1040-treated cells and control-treated cells in wild-type (WT) KRAS/BRAF SKOV3 cells. Tumours were excised and weighed. The data are expressed as the total tumour weight from each mouse. (C and D) Immunohistochemical staining of phosphorylated extracellular-regulated kinase 1/2 (p-ERK1/2) in tumours with KRAS mutant MDAH2774 cells. (C) Intense immunoreactivity is present in both the nucleus and the cytoplasm in CI-1040-untreated tumour. (D) Immunoreactivity is absent in both the nucleus and the cytoplasm in CI-1040-untreated tumour cells.